Novo Nordisk announced the availability of Ozempic (semaglutide) injection 1mg as a single pen containing four 1mg doses for monthly (1 injection/week) maintenance therapy.
Ozempic, a glucagon-like peptide-1 (GLP-1) receptor agonist, is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus (T2DM). It is also indicated to reduce the risk of major cardiovascular (CV) events (eg, CV death, non-fatal myocardial infarction, or non-fatal stroke) in adults with T2DM and established CV disease.
The Company is transitioning away from the currently available 2-pen packaging to the new single monthly pen device, which will contain a larger cartridge to hold four 1mg doses and will include 4 NovoFine Plus needles. A new prescription may be required to receive the new packaging, which will be available beginning in April.
According to the Company, the new device will not impact price, coverage, out-of-pocket cost, or the patient savings and support offerings. Existing patients may continue receiving Ozempic injection 1mg in a 2-pen packaging until the single monthly pen becomes readily available.
Pharmacists can access more information about how to dispense the new Ozempic 1mg 1-pen package by downloading the Ozempic Dispensing Quick Reference Guide.
Ozempic is also available as a single-patient-use pen delivering 0.25mg or 0.5mg per injection.
Novo Nordisk Transitions to Single Pen for Monthly Supply of Ozempic® (semaglutide) injection 1 mg. [press release]. Novo Nordisk; April 1, 2021.
This article originally appeared on MPR